Hubei Cancer Hospital ( Site 2203) — Wuhan, Hubei

Public research footprint of Hubei Cancer Hospital ( Site 2203), compiled from the ClinicalTrials.gov public registry.

365

Registered studies

222

Active

126

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Non-small Cell Lung Cancer · Metastatic Castration-resistant Prostate Cancer (mCRPC) · Esophageal Squamous Cell Carcinoma (ESCC) · Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recently updated registry entries

NCT06901531 — A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With… (Recruiting)
NCT04892173 — JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC (Recruiting)
NCT06662786 — A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI… (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Hubei Cancer Hospital ( Site 2203)?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 02, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.